[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XXX% no change
1 Month: XX% -XX%
6 Months: XX% +5%
1 Year: XX% -X%
1-Year High: XXX% on 2025-02-20
1-Year Low: XX% on 2025-02-01
Most Supportive Themes
- Positive Regulatory News and Approvals: (35%) Posts highlight positive regulatory events, such as FDA approvals for generic versions of Jazz Pharmaceuticals' drugs.
- Analyst Recommendations and Price Targets: (25%) Mentions of analyst ratings and price targets, which can influence investor sentiment and trading activity.
- Product Pipeline and Clinical Trials: (20%) Positive mentions of Jazz Pharmaceuticals' product pipeline, including Modeyso (dordaviprone) and its inclusion in NCCN guidelines.
Most Critical Themes
- Competition and Market Dynamics: (20%) Mentions of competition in the narcolepsy market, such as Avadel's Lumryz, and the impact on Jazz Pharmaceuticals' market share.
- Earnings Miss and Financial Performance: (10%) The company faced a miss in earnings expectations, with non-GAAP EPS of $1.68, which could be a concern for investors.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XXX | XX% | XXX | XX% | X | X% |
| Total | XXX | XX% | XXX | XX% | X | X% |